image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - JP
$ 15.045
-1.37 %
$ 47.7 B
Market Cap
34.48
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one TAK stock under the worst case scenario is HIDDEN Compared to the current market price of 15 USD, Takeda Pharmaceutical Company Limited is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one TAK stock under the base case scenario is HIDDEN Compared to the current market price of 15 USD, Takeda Pharmaceutical Company Limited is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one TAK stock under the best case scenario is HIDDEN Compared to the current market price of 15 USD, Takeda Pharmaceutical Company Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TAK

image
$15.5$15.5$15.0$15.0$14.5$14.5$14.0$14.0$13.5$13.5$13.0$13.0$12.5$12.515 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
4.26 REVENUE
5.87%
214 B OPERATING INCOME
-56.36%
144 B NET INCOME
-54.56%
716 B OPERATING CASH FLOW
-26.69%
-464 B INVESTING CASH FLOW
23.59%
-354 B FINANCING CASH FLOW
50.02%
1.18 REVENUE
-2.65%
184 B OPERATING INCOME
-16.14%
92 B NET INCOME
-3.36%
259 B OPERATING CASH FLOW
62.51%
-80 B INVESTING CASH FLOW
50.38%
-83.2 B FINANCING CASH FLOW
-25.08%
Balance Sheet Takeda Pharmaceutical Company Limited
image
Current Assets 2.56
Cash & Short-Term Investments 458 B
Receivables 698 B
Other Current Assets 1.4
Non-Current Assets 12.6
Long-Term Investments 431 B
PP&E 1.99
Other Non-Current Assets 10.1
3.03 %4.62 %9.29 %2.85 %13.17 %67.05 %Total Assets$15.1t
Current Liabilities 2.31
Accounts Payable 320 B
Short-Term Debt 367 B
Other Current Liabilities 1.63
Non-Current Liabilities 5.52
Long-Term Debt 5.03
Other Non-Current Liabilities 492 B
4.08 %4.69 %20.75 %64.20 %6.28 %Total Liabilities$7.8t
EFFICIENCY
Earnings Waterfall Takeda Pharmaceutical Company Limited
image
Revenue 4.26
Cost Of Revenue 1.43
Gross Profit 2.83
Operating Expenses 2.62
Operating Income 214 B
Other Expenses 70 B
Net Income 144 B
5t5t4t4t4t4t3t3t3t3t2t2t2t2t1t1t500b500b004t(1t)3t(3t)214b(70b)144bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
66.43% GROSS MARGIN
66.43%
5.02% OPERATING MARGIN
5.02%
3.38% NET MARGIN
3.38%
1.98% ROE
1.98%
0.95% ROA
0.95%
4.44% ROIC
4.44%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Takeda Pharmaceutical Company Limited
image
1t1t900b900b800b800b700b700b600b600b500b500b400b400b300b300b200b200b100b100b00(100b)(100b)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income 144 B
Depreciation & Amortization 728 B
Capital Expenditures -481 B
Stock-Based Compensation 70.9 B
Change in Working Capital -256 B
Others -24.7 B
Free Cash Flow 236 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Takeda Pharmaceutical Company Limited
image
TAK has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
2.19% DIVIDEND YIELD
0.319 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.900000.900000.800000.800000.700000.700000.600000.600000.500000.500000.400000.400000.300000.300000.200000.200000.100000.100000.000000.000000.365290.437050.398920.406430.417170.419050.340.275150.250.240.319160.365320.730.392420.830.399460.800.39550.800.411120.830.430530.850.330.670.270.550.261210.510.270.510.322015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Takeda Pharmaceutical Company Limited
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers BANNOCKBURN, Ill.--(BUSINESS WIRE)--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the en. businesswire.com - 2 weeks ago
TAK or DSNKY: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). zacks.com - 2 weeks ago
Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 2 weeks ago
Best Value Stocks to Buy for April 30th SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025. zacks.com - 2 weeks ago
Best Income Stocks to Buy for April 30th SKM, TAK and SONY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 30, 2025. zacks.com - 2 weeks ago
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world. businesswire.com - 2 weeks ago
New Strong Buy Stocks for April 30th DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025. zacks.com - 2 weeks ago
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 4 weeks ago
TAK vs. DSNKY: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). zacks.com - 1 month ago
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical trial of mezagitamab (TAK-079), identified from BioInvent's proprietary n-CoDeR® antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (ITP). accessnewswire.com - 1 month ago
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's Icotrokinra show strong Phase III results, with potential regulatory approvals and launches by 2026, boosting revenue prospects. Protagonist's financial stability, with a cash runway until 2028, supports a "Strong Buy" rating for high-risk tolerant investors. seekingalpha.com - 1 month ago
8. Profile Summary

Takeda Pharmaceutical Company Limited TAK

image
COUNTRY JP
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 47.7 B
Dividend Yield 2.19%
Description Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Contact 1-1, Nihonbashi-Honcho 2-chome, Tokyo, 103-8668 https://www.takeda.com
IPO Date Jan. 5, 2010
Employees 49281
Officers Dr. Seigo Izumo Chair of Management Board Mr. Christopher David O'Reilly Global Head of Investor Relations & Global Finance Mr. Iwaaki Taniguchi Senior Vice President of Corporate Finance & Controlling Department Mr. Haruhiko Hirate Member of Management Board Mr. Salvatore Alesci M.D., Ph.D. Member of Management Board and Head of R&D Global Science & Biomedical Policy Mr. Christophe Weber President, Chief Executive Officer & Representative Director Mr. Yoshihiro Nakagawa Global General Counsel Mr. Gabriele Ricci Chief Data & Technology Officer Mr. Milano Furuta Chief Financial Officer & Director Norimasa Takeda Chief Accounting Officer & Corporate Controller